Renal hemodialysis and maternal serum triple analyte screening

Lee P. Shulman*, Rodney Briggs, Owen P. Phillips, Steven A. Friedman, Baha Sibai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The obstetrical management of women with renal disease is complicated and associated with increased fetal and maternal morbidity. However, maternal serum screening is an integral part of obstetrical care and should be offered to all women. We found that maternal serum levels of α-fetoprotein and human chorionic gonadotropin did not significantly change as a result of hemodialysis, whereas levels of unconjugated estriol were markedly decreased following hemodialysis. Maternal serum screening should be limited to α-fetoprotein analysis in women undergoing hemodialysis until the effects of hemodialysis on all serum analytes are better delineated.

Original languageEnglish (US)
Pages (from-to)26-28
Number of pages3
JournalFetal Diagnosis and Therapy
Issue number1
StatePublished - Apr 28 1998


  • Dialysis
  • Maternal serum screening
  • Renal disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Radiology Nuclear Medicine and imaging
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Renal hemodialysis and maternal serum triple analyte screening'. Together they form a unique fingerprint.

Cite this